Mounjaro cost: the list price, the $25 card, and the $499 self-pay price

There are three Mounjaro prices. There is a list price. There is a copay for the insured. And there is a self-pay price through LillyDirect, starting at $499 a month at every strength, which is the number to use if you are paying cash.

The list price: $1,112.16 per fill

Lilly publishes it on its own pricing page: the list price "of Mounjaro is $1,112.16 per fill".¹ A fill is a month, four weekly pens. That is the wholesale acquisition cost, the number a pharmacy starts from when it bills someone with no coverage, and it is flat across doses, unlike Zepbound's.

Almost nobody pays it, and Lilly's own page is careful to say the amount you pay "will largely depend on your prescription drug insurance plan".¹ But it is the price behind every other number, and it is what you are looking at if you walk into a pharmacy uninsured with a Mounjaro prescription.

The insured price: as little as $25

For people with commercial insurance that covers Mounjaro, Lilly's card takes the copay down: "Eligible, commercially insured patients with Mounjaro coverage can pay as little as $25 for up to a 3-month prescription with the Mounjaro Savings Program."² Government plans are excluded, as with every manufacturer card.

The load-bearing word is coverage, and coverage follows the label. Mounjaro is approved "to improve blood sugar (glucose) in adults and children 10 years of age and older with type 2 diabetes mellitus", and to reduce cardiovascular risk in diabetic adults.² For those uses it is one of the most widely covered drugs in the country. Prescribed for weight loss it is refused almost everywhere, because it is not approved for that, and Lilly's site says so in bold: "Mounjaro is not a weight loss drug."² Here is where eight insurers stand, in their own words:

Every one of them says no to Mounjaro for weight. If you have type 2 diabetes, the $25 route is open. If you do not, the card is not your route, and the savings card guide explains the programme's caps and why Zepbound's card is structured differently.

The cash price: from $499 a month

Lilly's pricing page says people whose insurance does not cover Mounjaro, or who have none, "may be eligible for self-pay savings options".¹ LillyDirect puts a number on it: each of the six strengths is listed as "Self-pay price: Starting at $499/month".⁴ Unlike Zepbound, the price does not climb with the dose.

The terms behind the $499

The self-pay price comes with a short list of terms, and three of them decide whether it is your route. First, the prescription: the buyer confirms "I have been prescribed Mounjaro for an approved use consistent with the FDA-approved product labeling".⁵ Mounjaro's approved uses are type 2 diabetes and lowering cardiovascular risk in diabetic adults, so the $499 price is a diabetes price, not a weight-loss one. Second, the money does not move your insurance: you agree not to count what you pay "towards my insurance deductible or out-of-pocket spending requirements", and the terms extend that to Medicare Part D's out-of-pocket total.⁵ Third, the buyer must be 18 or older and live in the United States or Puerto Rico.⁵

Two smaller points help the budget. A fill is "four pens per month", so $499 buys a month at your dose, not a pen.⁵ And LillyDirect marks Mounjaro "FSA/HSA eligible", adding that "Eligibility may vary by plan", so pre-tax money may be able to pay the $499 even though it does not count toward the deductible.⁴

Zepbound is the comparison that matters, because Zepbound is tirzepatide and so is Mounjaro: the same molecule at the same six doses. Lilly sells Zepbound direct to cash patients at $299, $399, $499 and $699 a month by dose, through a programme it describes as "the price at which Lilly sells the product directly to patients".³ So at the starting doses Zepbound is cheaper, and from 10 mg Mounjaro's flat $499 is below Zepbound's regular $699.

What that means in dollars over a year

A Mounjaro fill is "four pens per month",⁵ four weekly doses, and Lilly defines a Zepbound month as "28 days per month".³ So a year of weekly doses is 13 fills, not 12, and the figures below count 13.

Coverage is still the biggest lever: about $325 a year with the card, against $6,487 on LillyDirect and more than $14,000 at list.

The third route: compounded tirzepatide

Because Mounjaro is tirzepatide, the cheap route is tirzepatide too. Licensed compounding pharmacies sell it through telehealth programs at prices that make even Zepbound's $699 look like a list price. Not FDA-approved as a finished product, which means no FDA review of the specific preparation for safety, effectiveness or quality, with the pharmacy's licensing in its place. From every seller we track, read from their own pages:

From $85 a month. Before choosing that route, check the seller; the price gap attracts the wrong pharmacies as well as the right ones.

What Mounjaro actually does for weight

Since most people asking about its cost are asking because of weight, the honest number from Lilly's own diabetes trials: weight loss in adults "ranged from 12 lb (5 mg) to 25 lb (15 mg)".² That is in people with type 2 diabetes, who lose less on these drugs than people without it. The same molecule in non-diabetic adults, in the Zepbound trials, produced 20.2% of body weight at 72 weeks in the only head-to-head; the tirzepatide vs semaglutide guide has the trial.

The honest summary

Mounjaro costs $1,112.16 a month at list, $25 a month with commercial coverage for diabetes, and from $499 a month self-pay through LillyDirect. If you have diabetes and coverage, it is among the cheapest drugs on this site to be on. If you are paying cash for weight, Zepbound from $299 or compounded tirzepatide from $85 cost less.